BBIO News and Press, BridgeBio Pharma Inc. From 11/24/23

2023-11-24 02:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001) - The placebo and acoramidis time-t...

PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinica...

2023-11-02 17:34:03 ET More on BridgeBio Pharma BridgeBio: Bets Acoramidis As The Pfizer Spoiler BridgeBio: Positive Updated Acoramidis Data May Not Imply Further Upside BridgeBio draws Buy rating at Cantor citing 100% upside BridgeBio Pharma to issue 9.2M sh...

2023-11-02 08:11:29 ET More on BridgeBio Pharma BridgeBio: Bets Acoramidis As The Pfizer Spoiler BridgeBio: Positive Updated Acoramidis Data May Not Imply Further Upside BridgeBio draws Buy rating at Cantor citing 100% upside BridgeBio Pharma to issue 9.2M sh...

- Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospitalized less than has been seen in other interventional studies of transthyretin amyloid cardiomyop...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

BridgeBio Pharma Inc. (BBIO) is expected to report $-0.86 for Q3 2023

2023-10-24 19:57:52 ET BridgeBio Pharma (NASDAQ: BBIO) had a good Tuesday on the stock exchange. Following the initiation of coverage by a veteran stock-tracking company, the commercial-stage biotech's share price experienced a nice boost to close the day more than 3% higher. That c...